Volume | 54,562 |
|
|||||
News | - | ||||||
Day High | 1.04 | Low High |
|||||
Day Low | 0.9401 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sensei Biotherapeutics Inc | SNSE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.04 | 0.9401 | 1.04 | 0.9917 | 0.9977 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
189 | 54,562 | $ 0.9789434 | $ 53,413 | - | 0.51 - 1.72 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:17:55 | formt | 100 | $ 1.02 | USD |
Sensei Biotherapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
24.07M | 25.07M | - | 0 | -34.1M | -1.36 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sensei Biotherapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SNSE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.9881 | 1.10 | 0.9101 | 0.9753267 | 48,603 | 0.0036 | 0.36% |
1 Month | 1.02 | 1.17 | 0.9101 | 1.04 | 91,529 | -0.0283 | -2.77% |
3 Months | 0.7449 | 1.22 | 0.74 | 0.9741975 | 73,019 | 0.2468 | 33.13% |
6 Months | 0.6297 | 1.22 | 0.51 | 0.8335949 | 71,616 | 0.362 | 57.49% |
1 Year | 1.40 | 1.72 | 0.51 | 0.9273296 | 47,958 | -0.4083 | -29.16% |
3 Years | 13.19 | 15.12 | 0.51 | 4.55 | 75,892 | -12.20 | -92.48% |
5 Years | 24.70 | 26.38 | 0.51 | 6.95 | 86,504 | -23.71 | -95.99% |
Sensei Biotherapeutics Description
Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. The company's ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused, and coordinated innate and adaptive immune response. |